The study met its primary endpoint in all groups receiving doses of TV-‘749 compared to the placebo group, achieving clinically remarkable and statistically significant reductions in total score on the Positive and Negative Symptom Scale (PANSS), a widely used assessment tool to gauge the severity of schizophrenia symptoms.
TV-‘749 was well tolerated, no cases of post-injection delirium/sedation syndrome (PDSS) have been observed so far: additional safety data are being collected in the follow-up study at long term SOLARIS.
mdc-TJK (TV-‘749) is a long-acting monthly subcutaneous injection of olanzapine, a 2nd generation antipsychotic, developed by Teva using Medincell’s SteadyTeq™ copolymer technology.